

#AAD2019

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Scientific Initiative of:



Sponsored by:



#AAD2019

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Onychology and trichology
Dra. Ángela Hermosa Gelbard

Scientific Initiative of:



Sponsored by:



- **S023. Hair disorders Made easier**
- **Diagnosis in non- scarring alopecia- Tosti**
 - Androgenetic alopecia
 - Peripilar sign → early diagnosis
 - Focal atrichia → mostly seen in postmenopausal women. Empty follicles and yellow dots with very thin short vellus hairs
 - Clue to distinguish vellus hairs vs regrowing hairs → Thickness
 - Alopecia areata
 - In dark skin instead of yellow dots , there are White dots
- **Pearls in the management of scarring alopecia- Dr. Elston**
 - In scalp biopsy → Surgifoam
 - Therapeutic options in DF: colchicine / dapsone

- **Treatment and follow up in non-scarring alopecia- Dr. Saphiro**
- **AGA**
 - AGA can be unmasked and made worse by the episodes of telogen effluvium
 - 1º minoxidil 5% → 2º add spironolactone or finasteride or dutasteride
 - PRP Protocol
 - 2 PRP sessions at 1 month intervals → if no succesfull response, STOP
 - →if succesfull, continue monthly PRP for more 4 months and reevaluate
 - NEVER PRP if scalp cáncer
- **Alopecia areata**
 - Intralesional ac. Triamcinolone
 - Low concentration (2,5 mg/cc) with higher volumes
 - 9 cc per treatment: 8 cc for the scalp, 1 cc for the eyebrows
 - In extensive forms
 - Contact immunotherapy
 - Tofacitinib associated to intralesional corticosteroids
 - PRP

- **S032. Alopecia work up and treatment**
- **Alopecia areata: why, what, how and when to treat- R. Sinclair**
 - Possible indications for systemic treatment
 - Rapid hair loss.
 - Extensive disease (>20% hair loss)
 - Chronic AA (>12m)
 - Severe distress
 - Current available systemic treatments: **Glucocorticosteroids**, MTX, CsA, azathioprine, dapson, mycophenolate mofetil, tacrolimus and sulfasalazine
- **Updates On JAK inhibitors for Alopecia areata- Dr. King**
 - Tofacitinib (5mg BID) and ruxolitinib (10 g BID) are effective for severe AA.
 - Evaluate Q12wk, consider increase dose if hair regrowth inadequate
 - Expect near-complete hair regrowth over **6-9 months**
 - Treatment is necessary for maintenance of hair regrowth, if taper, do very slowly over **at least 1 year**
 - Scalp usually responds better than eyebrows and eyelashes
 - Unclear if topical JAKi will be effective

- **Medically Maximizing Male and female pattern Hair Loss- Dr. Donovan**
 - **Methods of getting more minoxidil to the follicle**
 - Minoxidil+ Dermarolling
 - Minoxidil 7.5%
 - Minoxidil 5%+ azelaic acid 5%+ tretinoin 0,01%
 - Oral minoxidil (0,25-5mg)
 - **Oral minoxidil side effects**
 - Headaches, dizziness (1-2%)
 - Ankle swelling (1-2%)
 - Increased hair on face (15-25%)
 - Rashes and hives (15%)
 - **Off label finasteride treatment options to reduce side effects**
 - A) Lower finasteride doses (0,2 mg)
 - B) Topical finasteride 0,25% solution (inhibits DHT similar to 1 mg oral)
 - **Dutasteride in real practice**
 - Option 1: Switch to dutasteride if patient not responding to finasteride
 - Option 2: Continue finasteride and add 0,5 mg dutasteride on weekend
 - **Micro-inflammation in androgenetic alopecia**
 - Corticosteroids or antifungal products



- **Safety of 5ARI and spironolactone in breast cancer patients receiving endocrine therapies**
 - Spironolactone has the potential to be used as a relative safe option for the management of EIA in female breast cancer patients who respond poorly to topical minoxidil
- **Prevention of taxane induced alopecia and nail toxicity:**
 - Effective interventions to prevent hair loss: cold caps, scalp cooling
 - Effective interventions to prevent nail changes: frozen gloves, hydrating nail solution
- **Use of oral supplements in patients with hair loss disorders**
 - Biotin can falsely lower cardiac troponin levels and lead to misdiagnosis of myocardial infarction and also can falsely elevate thyroid function tests